

# Jan Sperl

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1734174/publications.pdf>

Version: 2024-02-01

68  
papers

7,003  
citations

279798

23  
h-index

155660

55  
g-index

69  
all docs

69  
docs citations

69  
times ranked

6245  
citing authors

#	ARTICLE	IF	CITATIONS
1	HCV Elimination in Central Europe with Particular Emphasis on Microelimination in Prisons. <i>Viruses</i> , 2022, 14, 482.	3.3	9
2	Liver stiffness measured by two-dimensional shear-wave elastography predicts hepatic vein pressure gradient at high values in liver transplant candidates with advanced liver cirrhosis. <i>PLoS ONE</i> , 2021, 16, e0244934.	2.5	6
3	Is elimination of HCV in 2030 realistic in Central Europe. <i>Liver International</i> , 2021, 41, 56-60.	3.9	9
4	Therapy of chronic hepatitis C in people who inject drugs: focus on adherence. <i>Harm Reduction Journal</i> , 2021, 18, 69.	3.2	16
5	Portal hypertension is the main driver of liver stiffness in advanced liver cirrhosis. <i>Physiological Research</i> , 2021, 70, 563-577.	0.9	7
6	Alpha-1 Antitrypsin and Hepatocellular Carcinoma in Liver Cirrhosis: SERPINA1 MZ or MS Genotype Carriage Decreases the Risk. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10560.	4.1	8
7	Chronic hepatitis C virus infection in the Czech Republic and Slovakia: an analysis of patient and virus characteristics. <i>International Journal of Public Health</i> , 2020, 65, 1723-1735.	2.3	0
8	How close are we to hepatitis C virus elimination in Central Europe?. <i>Clinical and Experimental Hepatology</i> , 2020, 6, 1-8.	1.3	11
9	PNPLA3 rs738409 G allele carriers with genotype 1b HCV cirrhosis have lower viral load but develop liver failure at younger age. <i>PLoS ONE</i> , 2019, 14, e0222609.	2.5	3
10	IL28B rs12979860 T allele protects against CMV disease in liver transplant recipients in the post-transplant prophylaxis and late period. <i>Transplant Infectious Disease</i> , 2019, 21, e13124.	1.7	5
11	Elbasvir/grazoprevir in women with hepatitis C virus infection taking oral contraceptives or hormone replacement therapy. <i>International Journal of Women's Health</i> , 2019, Volume 11, 617-628.	2.6	2
12	Chronic hepatitis C in the Czech Republic: Forecasting the disease burden. <i>Central European Journal of Public Health</i> , 2019, 27, 93-98.	1.1	4
13	Donor PNPLA3 rs738409 genotype is a risk factor for graft steatosis. A post-transplant biopsy-based study. <i>Digestive and Liver Disease</i> , 2018, 50, 490-495.	0.9	25
14	Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Regimen in the Treatment of Genotype 1 Chronic Hepatitis C Infection in Patients with Severe Renal Impairment and End-Stage Renal Disease: a Real-Life Cohort. <i>Kidney and Blood Pressure Research</i> , 2018, 43, 594-605.	2.0	20
15	The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection. <i>Journal of Gastroenterology</i> , 2018, 53, 679-688.	5.1	43
16	Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 125-133.	8.1	128
17	Patient-reported outcomes in individuals with hepatitis C virus infection treated with elbasvir/grazoprevir. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 2631-2638.	1.8	7
18	Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 325-336.	8.1	208

#	ARTICLE	IF	CITATIONS
19	Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis. Therapeutics and Clinical Risk Management, 2017, Volume 13, 733-738.	2.0	15
20	Direct-acting antivirals in the treatment of HCV-associated malignant lymphomas. Gastroenterologie A Hepatologie, 2017, 71, 138-144.	0.1	1
21	Clinical practice guidelines for chronic hepatitis C virus infection. Gastroenterologie A Hepatologie, 2017, 71, 117-136.	0.1	0
22	Czech Society of Hepatology guidelines for diagnosis and treatment of acute porphyrias. Gastroenterologie A Hepatologie, 2017, 71, 101-104.	0.1	0
23	Hepatology topics of special interest from Central Europe (Czech Republic, Hungary, Poland,) Tj ETQq1 1 0.784314, rgBT /Overlock 10	1.8	0
24	Sal600 Treatment of Uncontrollable Acute Variceal Bleeding With Self-Expanding Metal Stent: A Single Center Experience. Gastroenterology, 2016, 150, S339.	1.3	2
25	Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. Hepatology, 2016, 64, 1249-1264.	7.3	550
26	Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial. Journal of Hepatology, 2016, 65, 1112-1119.	3.7	45
27	Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure. Journal of Hepatology, 2016, 64, 574-582.	3.7	196
28	Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology, 2015, 62, 243-252.	7.3	493
29	Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load ( $\geq 9 \log_{10}$ copies/ml). Liver International, 2015, 35, 422-428.	3.9	6
30	USP18 downregulation in peripheral blood mononuclear cells predicts nonresponse to interferon-based triple therapy in patients with chronic hepatitis C, genotype 1: a pilot study. Therapeutics and Clinical Risk Management, 2015, 11, 1853.	2.0	2
31	The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. Journal of Hepatology, 2015, 62, 831-840.	3.7	289
32	Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection. World Journal of Gastroenterology, 2015, 21, 5496.	3.3	8
33	Standard diagnostic and therapeutic approaches to chronic hepatitis C virus infection. Gastroenterologie A Hepatologie, 2015, 69, .	0.1	0
34	P15: The IFNL4 DG/TT genotyping does not improve prediction of SVR in HCV-infected patients in the Czech Republic. Journal of Viral Hepatitis, 2014, 21, 29-30.	2.0	0
35	Strategies to manage hepatitis C virus (HCV) disease burden. Journal of Viral Hepatitis, 2014, 21, 60-89.	2.0	161
36	The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. Journal of Viral Hepatitis, 2014, 21, 34-59.	2.0	372

#	ARTICLE	IF	CITATIONS
37	Historical epidemiology of hepatitis C virus (<scp>HCV</scp>) in selected countries. Journal of Viral Hepatitis, 2014, 21, 5-33.	2.0	211
38	Genetic variation in TNFA predicts protection from severe bacterial infections in patients with end-stage liver disease awaiting liver transplantation. Journal of Hepatology, 2014, 60, 773-781.	3.7	7
39	Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. Journal of Hepatology, 2014, 61, 1038-1047.	3.7	741
40	Incidental Hepatocellular Carcinoma: Risk Factors and Long-Term Outcome After Liver Transplantation. Transplantation Proceedings, 2014, 46, 1426-1429.	0.6	23
41	<i>ABCB4</i> mutations underlie hormonal cholestasis but not pediatric idiopathic gallstones. World Journal of Gastroenterology, 2014, 20, 5867.	3.3	21
42	Standard diagnostic and therapeutic procedure for chronic infection of hepatitis C virus. Gastroenterologie A Hepatologie, 2014, 68, 499-512.	0.1	0
43	Recommended procedure for diagnosis and treatment of chronic hepatitis B. Gastroenterologie A Hepatologie, 2014, 68, 514-526.	0.1	2
44	Further evidence of the benefits associated with antiviral treatment in kidney allograft recipients with chronic hepatitis B virus infection. Journal of Hepatology, 2013, 58, 833-835.	3.7	3
45	Urgent Liver Transplantation for Chemotherapy-Induced HBV Reactivation: A Suitable Option in Patients Recently Treated for Malignant lymphoma. Transplantation Proceedings, 2013, 45, 2834-2837.	0.6	9
46	Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis. Gastroenterology, 2013, 144, 1426-1437.e9.	1.3	2,211
47	Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology, 2013, 58, 505-513.	7.3	104
48	FAT MASS AND OBESITYâ€ASSOCIATED (FTO) GENE AND ALCOHOL INTAKE. Addiction, 2012, 107, 1185-1186.	3.3	7
49	Glycyrrhizin in patients who failed previous interferon alphaâ€based therapies: biochemical and histological effects after 52â€weeks. Journal of Viral Hepatitis, 2012, 19, 537-546.	2.0	62
50	De novo Malignancies After Orthotopic Liver Transplantation (OLT) Do Not Compromise the Outcome. Gastroenterology, 2011, 140, S-962.	1.3	0
51	Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Hepatology, 2010, 52, 1201-1207.	7.3	63
52	Farglitazar Lacks Antifibrotic Activity in Patients With Chronic Hepatitis C Infection. Gastroenterology, 2010, 138, 1365-1373.e2.	1.3	86
53	Do common genetic variants in endotoxin signaling pathway contribute to predisposition to alcoholic liver cirrhosis?. Clinical Chemistry and Laboratory Medicine, 2009, 47, 398-404.	2.3	10
54	N -acetyl cysteine averted liver transplantation in a patient with liver failure caused by erythropoietic protoporphyria. Liver Transplantation, 2009, 15, 352-354.	2.4	7

#	ARTICLE	IF	CITATIONS
55	Frequent and Various Biliary Complications Did Not Compromise the Outcome of Orthotopic Liver Transplantation (OLT): Ten Years Experience with 500 Consecutive Patients. Gastrointestinal Endoscopy, 2008, 67, AB170.	1.0	0
56	Acute rejection of non-functional allograft in kidney transplant recipients with hepatitis C treated with peginterferon- $\alpha$ 2a. Journal of Hepatology, 2008, 49, 461-462.	3.7	5
57	72 TENOFOVIR DISOPROXIL FUMARATE (TDF) FOR THE TREATMENT OF HBEAG-POSITIVE CHRONIC HEPATITIS B: WEEK 72 TDF DATA AND WEEK 24 ADEFOVIR DIPIVOXIL SWITCH DATA (STUDY 103). Journal of Hepatology, 2008, 48, S32.	3.7	31
58	877 TEMPORARY NASOBILIARY DRAINAGE INDUCES RELIEF FROM SEVERE LONG-LASTING PRURITUS IN DRUG-INDUCED CANALICULAR CHOLESTASIS. Journal of Hepatology, 2008, 48, S329.	3.7	0
59	888 IMPROVEMENT OF LIVER DYSFUNCTION AFTER TREATMENT WITH N-ACETYL CYSTEINE IN PATIENT WITH ERYTHROPOIETIC PROTOPORHYRIA. Journal of Hepatology, 2008, 48, S333.	3.7	0
60	Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial. Hepatology, 2008, 47, 1604-1614.	7.3	266
61	The effect of severe hepatic impairment on the pharmacokinetics and haematological response of C.E.R.A.. Current Medical Research and Opinion, 2008, 24, 1943-1950.	1.9	5
62	[751] HIGH SECRETORY HAPLOTYPE OF INTERLEUKIN-1 GENE CLUSTER INCREASES THE RISK OF ALCOHOLIC LIVER CIRRHOSIS. Journal of Hepatology, 2007, 46, S282.	3.7	0
63	Revised King's College score for liver transplantation in adult patients with Wilson's disease. Liver Transplantation, 2007, 13, 55-61.	2.4	51
64	Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. Journal of Hepatology, 2006, 44, 97-103.	3.7	418
65	Liver Transplantation in Eastern Europe. Liver Transplantation, 2000, 6, 665-669.	2.4	6
66	Liver transplantation for fulminant Wilson's disease, the significance of prothrombin time on admission. Gastroenterology, 2000, 118, A1495.	1.3	0
67	Use of $^{31}\text{P}$ MR spectroscopy in liver cirrhosis. Journal of Hepatology, 2000, 32, 156.	3.7	1
68	The process of continuous production and isolation of coproporphyrin. Biotechnology Letters, 1988, 10, 273-276.	2.2	0